Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares were down 1.3% on Thursday. The stock traded as low as C$14.90 and last traded at C$14.90. 280 shares were traded during mid-day trading, a decline of 100% from the average session volume of 169,589 shares. The stock had previously closed at C$15.10.
Oncolytics Biotech Stock Performance
The firm’s 50 day moving average price is C$14.90 and its 200-day moving average price is C$14.90. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 17.78, a current ratio of 2.82 and a quick ratio of 8.86.
About Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
